Definium Q3 Reaffirms Strength, But Valuation and New Patent Concerns Keep Rating at WAIT

What happened

Definium reported Q3 earnings, reiterating strong Phase 3 results for DT120 in GAD and MDD and positioning for an NDA filing expected in 1H 2027 (not 2026 as erroneously stated in the Seeking Alpha article). The company's cash position remains robust at over $1 billion. However, a new Seeking Alpha article maintains a Hold rating, citing high valuation, patent challenges, and uncertain market dynamics. Our existing WAIT rating remains appropriate; the article adds patent risk to our concern list but does not alter the fundamental risk/reward. The stock continues to trade above our attractive entry level, suggesting patience for a better opportunity.

Implication

Investors should hold DFTX and avoid new buying at current levels. The pre-NDA meeting in 4Q26 is the next critical catalyst; any FDA requests for additional CMC, safety, or bridging work could delay the NDA and pressure the stock. Valuation remains excessive relative to the company's pre-revenue status and execution risks, and the newly highlighted patent challenges add another layer of uncertainty. A pullback toward $31 would offer a more attractive entry, while trimming above $44 remains prudent. Monitor detailed Panorama data, commercial readiness disclosures, and any changes to the NDA timeline for signals to adjust positioning.

Thesis delta

No change to the overall WAIT rating. The new article introduces patent challenges as a specific risk, which we had not emphasized, but the robust Q3 results and ample cash do not address our primary concerns about valuation and regulatory/commercial execution. We maintain our view: attractive entry around $31, trim above $44.